Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: J Dermatol. 2012 Apr 9;39(7):617–624. doi: 10.1111/j.1346-8138.2012.01553.x

Figure 5. HSKs treated with decitabine followed by doxorubicin show reduced expression of mir-145 and OCT4.

Figure 5

HSKs were treated with doxorubicin alone, decitabine alone, or decitabine for 31 hours followed by doxorubicin for 6 hours. Note, co-treatment reduces the decitabine-induced increase in OCT4 and mir-145 13-fold and 9-fold, respectively. n = 3 for each group.